DiaMedica Therapeutics Inc expected to post a loss of 19 cents a share - Earnings Preview
01/08/2025 12:21
DiaMedica Therapeutics Inc DMAC.OQ DMAC.O is expected to show no change in quarterly revenue when it reports results on August 5 (estimated) for the period ending June 30 2025 LSEG's mean analyst estimate for DiaMedica Therapeutics Inc is for a loss of 19 cents per share. The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 3 "strong buy" or "buy," no "hold" and no "sell" or "strong sell." The mean earnings estimate of analysts was unchanged in the last three months. Wall Street's median 12-month price target for DiaMedica Therapeutics Inc is $12.00, about 64.8% above its last closing price of $4.22 Previous quarterly performance (using preferred earnings measure in US dollars).
| QUARTER ENDING | STARMINESMARTESTIMATE® | LSEG IBES ESTIMATE | ACTUAL | BEAT, MET, MISSED | SURPRISE % |
| Mar. 31 2025 | -0.17 | -0.18 | -0.18 | Met | 0 |
| Dec. 31 2025 | -0.17 | -0.18 | Missed | -4.3 | |
| Sep. 30 2024 | -0.15 | -0.15 | -0.15 | Met | 3.2 |
| Jun. 30 2024 | -0.15 | -0.16 | -0.13 | Beat | 17 |
| Mar. 31 2024 | -0.16 | -0.16 | -0.14 | Beat | 10.6 |
| Dec. 31 2023 | -0.14 | -0.14 | Met | 0 | |
| Sep. 30 2023 | -0.14 | -0.13 | -0.12 | Beat | 5.3 |
| Jun. 30 2023 | -0.19 | -0.18 | -0.16 | Beat | 9.4 |
Recent news on DiaMedica Therapeutics
See all newsBrief: Diamedica Therapeutics Announces Enrollment Of 200Th Patient In Remedy2 Phase 2/3 Acute Ischemic Stroke Trial
DiaMedica Q2 net loss widen less than expected
DiaMedica Therapeutics Inc expected to post a loss of 20 cents a share - Earnings Preview
U.S. STOCKS ON THE MOVE-Qualcomm, Robinhood
Brief: Diamedica Receives FDA Feedback On Dm199 Preeclampsia Nonclinical Program